Clinical Trial Update: Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 efficacy and safety study of abatacept for lupus nephritis in systemic lupus erythematosus has been terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Systemic Lupus Erythematosus | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2012-05-11